References
Van Groeningen CJ, Godefridus JP, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772–2779.
Ito S, Tanaka A. Three cases of corneal disorders associated with an oral anticancer drug S-1. Nippon Ganka Gakkai Zasshi 2006; 110:919–923.
Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol 2005;140:325–327.
Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002;120:1180–1182.
Tsuchiya M, Hayasaka S, Mizuno K. Affi nity of ocular acid-insoluble melanin for drugs in vitro. Invest Ophthalmol Vis Sci 1987;28:822–825.
Chikama T, Takahashi N, Wakuta M, et al. Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1. Mol Vis 2009;15:2896–2904.
Hayashi T, Yamaguchi S, Kito S, et al. An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study. J Toxicol Sci 1996;21:527–544.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kobashi, H., Kamiya, K. & Shimizu, K. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1. Jpn J Ophthalmol 55, 163–165 (2011). https://doi.org/10.1007/s10384-010-0917-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-010-0917-7